Abeona Therapeutics financials
$5.16−2.46%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.4M | $8.7M | $5.4M | $0.00 | $400.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $7.2M | $6.0M | $4.4M | -$488.0K | $400.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | 63.3% | 69.1% | 80.7% | — | 100.0% | — | — | — | — | — | — | — |
| Operating income | -$13.7M | -$23.0M | -$22.9M | -$24.0M | -$22.8M | -$19.7M | -$16.7M | -$15.3M | -$17.9M | -$14.3M | -$13.2M | -$11.3M |
| Net income | -$20.2M | -$17.1M | -$20.5M | -$5.2M | $108.8M | -$12.0M | -$9.3M | -$30.3M | $7.4M | -$31.6M | -$16.6M | -$11.8M |
| Net margin | −177.4% | −195.8% | −377.5% | — | 27208.3% | — | — | — | — | — | — | — |
| Diluted EPS | $-0.35 | $-0.30 | $-0.22 | $-0.10 | $1.71 | $-0.24 | $-0.25 | $-0.63 | $-0.26 | $-1.16 | $-0.64 | $-0.48 |
| EBITDA | -$13.0M | -$22.3M | -$22.0M | -$23.4M | -$22.2M | -$19.2M | -$16.1M | -$14.9M | -$17.4M | -$13.8M | -$12.7M | -$10.8M |
| Operating cash flow | -$17.5M | -$19.8M | -$18.0M | -$21.2M | -$18.8M | -$18.4M | -$16.6M | -$12.2M | -$12.7M | -$14.5M | -$9.2M | -$5.7M |
| Free cash flow | -$18.0M | -$20.7M | -$19.1M | -$23.7M | -$21.7M | -$19.8M | -$17.2M | -$12.6M | -$13.4M | -$15.3M | -$9.3M | -$5.8M |
| Diluted shares | 57.0M | 56.6M | 93.9M | 54.2M | 66.6M | 49.8M | 37.6M | 48.1M | 51.2M | 27.3M | 25.8M | 24.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $56.2M | $61.4M | $78.4M | $82.9M | $163.5M | $15.9M |
| Short-term investments | $90.6M | $106.9M | $113.0M | $124.2M | $62.0M | $68.2M |
| Total debt | $15.0M | $18.1M | $20.0M | $19.8M | $19.6M | $19.3M |
| Total assets | $179.5M | $198.5M | $219.6M | $231.1M | $246.2M | $99.4M |
| Total liabilities | $51.4M | $53.6M | $60.4M | $59.9M | $82.7M | $58.0M |
| Shareholders' equity | $128.1M | $144.9M | $159.2M | $171.2M | $163.6M | $41.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology